REAL-LIFE COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER IMATINIB FAILURE FOR CHRONIC PHASE CML

被引：0

作者：

Tiribelli, M. ^{[1
]}

Bonifacio, M. ^{[2
]}

Binotto, G. ^{[3
]}

Iurlo, A. ^{[4
,5
]}

Cibien, F. ^{[6
]}

Maino, E. ^{[7
]}

Guella, A. ^{[8
]}

Festini, G. ^{[9
]}

Minotto, C. ^{[10
]}

De Biasi, E. ^{[11
]}

De Marchi, F. ^{[12
]}

Scaffidi, L. ^{[2
]}

Frison, L. ^{[13
]}

Bucelli, C. ^{[4
,5
]}

Medeot, M. ^{[1
]}

Calistri, E. ^{[14
]}

Sancetta, R. ^{[7
]}

Stulle, M. ^{[9
]}

Krampera, M. ^{[2
]}

Gherlinzoni, F. ^{[15
]}

Semenzato, G. ^{[3
]}

Ambrosetti, A. ^{[2
]}

Fanin, R. ^{[1
]}

机构：

[1] Azienda Osped Univ Udine, Div Hematol & BMT, Udine, Italy

[2] Univ Verona, Sect Hematol, Dept Med, Verona, Italy

[3] Univ Padua, Hematol Sect, Dept Med, Sch Med, Padua, Italy

[4] IRCCS Ca Granda Maggiore Policlin Hosp Fdn, Oncohematol Div, Milan, Italy

[5] Univ Milan, Milan, Italy

[6] Ca Foncello Hosp, Hematol Unit, Treviso, Italy

[7] DellAngelo Hosp, Hematol Unit, Venice, Italy

[8] Santa Chiara Hosp, Hematol Unit, Trento, Italy

[9] AOU Ospedali Riuniti, Div Clin Hematol, Trieste, Italy

[10] ULSS 13, Dept Med Special, Oncol & Oncohematol Unit, Venice, Italy

[11] P Cosma Hosp, Hematol Unit, Padua, Italy

[12] Azienda Osped Univ Udine, Div Hematol & BMT, Udine, Italy

[13] HemPadua Univ, Sch Med, Dept Med, Dept Med,Hematol Sect, Padua, Italy

[14] Ca Foncello Hosp, Hematol Unit, Treviso, Italy

[15] Ca Foncello Hosp, Hematol Unit, Treviso, Italy

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P612

引用

页码：237 / 238

页数：2

共 50 条

[31] Compassionate use experience with dasatinib therapy in patients after imatinib and/or nilotinib failure [J].

Gunawardena, Bettina A. ;

Schlief, Sarah ;

Dempke, Wolfram ;

Wnterhalter, Bernd .

BLOOD, 2007, 110 (11) :212B-212B

[32] Incidence of grade 3/4 adverse events in imatinib resistant/intolerant chronic phase CML (CP-CML): A comparison of nilotinib and dasatinib [J].

Carpiuc, K. T. ;

Stephens, J. M. ;

Liou, S. Y. ;

Botteman, M. F. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

[33] A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib [J].

Ernst, Thomas ;

Gruber, Franz X. ;

Pelz-Ackermann, Oliver ;

Maier, Jacqueline ;

Pfirrmann, Markus ;

Mueller, Martin C. ;

Mikkola, Ingvild ;

Porkka, Kimmo ;

Niederwieser, Dietger ;

Hochhaus, Andreas ;

Lange, Thoralf .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (09) :1227-1235

[34] BCR-ABL kinase domain mutations and their kinetics on second line dasatinib or nilotinib therapy in CML patients after imatinib failure: A cooperative evaluation of four different detection methods [J].

Ernst, Thomas ;

Gruber, Franz ;

Pelz-Ackermann, Oliver ;

Mueller, Martin C. ;

Mikkola, Ingvild ;

Porkka, Kimmo ;

Niederwieser, Dietger ;

Hochhaus, Andreas ;

Lange, Thoralf .

BLOOD, 2007, 110 (11) :101A-101A

[35] Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia [J].

Yood, Marianne Ulcickas ;

Oliveria, Susan A. ;

Cziraky, Mark ;

Hirji, Ishan ;

Hamdan, Muhammad ;

Davis, Catherine .

CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (02) :213-219

[36] Nilotinib As Second-Line Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase: Thailand Experience [J].

Chansung, Kanchana ;

Sirijerachai, Chittima ;

Lekhakula, Arnuparp ;

Viboonjuntra, Pongtep ;

Niparuck, Pimjai ;

Pauvilai, Teeraya ;

Numbenjapon, Tontanai ;

Bunworasate, Udomsak ;

Nawarawong, Weerasak ;

Tantiworawit, Adisak ;

Suwanban, Tawatchai ;

Jootar, Saengsuree .

BLOOD, 2016, 128 (22)

[37] Imatinib as Second-Line Therapy, Ameliorates or Maintains Molecular Responses Obtained with Ponatinib First-Line in Chronic Phase CML Patients [J].

Nicolini, Franck E. ;

Fossard, Gaelle ;

Coiteux, Valerie ;

Dubruille, Viviane ;

Alcazer, Vincent ;

Sobh, Mohamad ;

Mouchel, Pierre ;

Mahon, Francois-Xavier ;

Etienne, Gabriel ;

Guerci, Agnes .

BLOOD, 2016, 128 (22)

[38] Incidence of hyperlipidemia among patients with chronic myelogenous leukemia (CML) receiving first or second line therapy with dasatinib or nilotinib [J].

Franklin, Meg ;

Burns, Leah ;

Perez, Samuel ;

Yerragolam, Deepak ;

Makenbaeva, Dinara .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[39] Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib [J].

Cortes, Jorge E. ;

Khoury, Hanna J. ;

Kantarjian, Hagop M. ;

Lipton, Jeff H. ;

Kim, Dong-Wook ;

Schafhausen, Philippe ;

Matczak, Ewa ;

Leip, Eric ;

Noonan, Kay ;

Bruemmendorf, Tim H. ;

Gambacorti-Passerini, Carlo .

AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (12) :1206-1214

[40] Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs. [J].

Rossi, Antonella Russo ;

Breccia, Massimo ;

Castagnetti, Fausto ;

Luciano, Luigiana ;

Gozzini, Antonella ;

Annunziata, Mario ;

Martino, Bruno ;

Stagno, Fabio ;

Cavazzini, Francesco ;

Tiribelli, Mario ;

Visani, Giuseppe ;

Pregno, Patrizia ;

Musto, Pellegrino ;

Fava, Carmen ;

Avanzini, Paolo ;

Turri, Diamante ;

Sgherza, Nicola ;

Albano, Francesco ;

Specchia, Giorgina .

BLOOD, 2010, 116 (21) :946-946

← 1 2 3 4 5 →